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Antidepressants are often only moderately successful in decreasing the severity 
of depressive symptoms. In part, antidepressant treatment response in patients 
with depression is genetically determined. However, although a large number of 
studies have been conducted aiming to identify genetic variants associated with 
antidepressant drug response in depression, only a few variants have been repeatedly 
identified. Within the present review, we will discuss the methodological challenges 
and limitations of the studies that have been conducted on this topic to date (e.g., 
‘treated-only design’, statistical power) and we will discuss how specifically drug–
gene interaction models can be used to be better able to identify genetic variants 
associated with antidepressant drug response in depression. 
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Background
The lifetime prevalence of major depres-
sive disorder (MDD) is approximately 
12–18% in American and European popu-
lations [1–4], with a higher disease burden 
in female (notably two-times as high as in 
men) and older populations [1,5]. MDD is 
usually treated with psychotherapy or with 
antidepressant drug treatment, the latter 
being frequently divided in three main drug 
classes that affect different neurotransmit-
ter pathways by inhibiting or enhancing 
signal transduction across neurons: classical 
tricyclic anti depressants (TCAs); selective 
serotonin reuptake inhibitors (SSRIs); and 
other anti depressants (e.g., venlafaxine and 
mirtazapine). For example, SSRIs affect the 
seroto nergic signaling pathway by inhibiting 
serotonin reuptake from the synaptic cleft 
of serotonergic presynaptic neurons. This 
inhibition of serotonin reuptake results in a 
higher bioavailability of serotonin to post-
synaptic neurotransmitter signaling path-
ways. Alternatively, TCAs affect several 
neurotransmitter signaling pathways, includ-
ing dopaminergic, noradrenergic and sero-
tonergic signaling pathways. As TCAs work 
through multiple neurotransmitter path-
ways, adverse drug reactions are more com-
mon with TCAs than with SSRIs. Because of 
the lower risk of adverse drug reactions dur-
ing the use of SSRIs than during the use of 
TCAs, SSRIs are also more frequently used 
for the treatment of depressive indications [6]. 
Out of these two main antidepressant drug 
classes, most recent studies have been focused 
on the SSRIs.
Despite the fact that multiple antidepres-
sant drugs have been launched on the mar-
ket during the past decades, failure of anti-
depressant treatment, defined as insufficient 
decrease in depressive symptoms within a 
certain period of time, is common [7], and 
may be partly genetically determined [8–10]. 
Genes affecting antidepressant drug response 
have all been identified in candidate gene 
studies, in which a gene was tested in relation 
with antidepressant drug response in depres-
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sion on the basis of a predefined hypothesis [11,12]. 
Within these efforts, multiple genes have been iden-
tified that potentially affect antidepressant treatment 
response in depression [11,12]. However, heterogeneity 
of the findings between studies was large [12], and only 
few genes were well replicated in more recent stud-
ies or were only associated with antidepressant drug 
response in depression in subsequent studies com-
prising patients with specific subtypes of depression 
(e.g., melancholic or psychotic depression [13,14]). For 
this reason, only few genes have been repeatedly asso-
ciated with anti depressant drug response in depression 
in meta- analyses [12].
There are two biological processes governing the 
success of antidepressant drug treatment: pharmaco-
kinetics and pharmaco dynamics. For this reason, 
genetic studies on antidepressant drug response in 
depression have primarily evaluated genes encoding 
proteins that affect the pharmaco kinetics of an antide-
pressant drug (e.g., drug metabolism) or genes encod-
ing proteins that affect pharmaco dynamics (e.g., treat-
ment target). With respect to genes that affect 
antidepressant pharmaco kinetics, two independent 
genes have to date been repeatedly identified in relation 
to antidepressant drug response in depression, CYP2D6 
and ABCB1 [11,12]. In addition to antidepressant drug 
response in depression, these two genes have also been 
associated with the risk of adverse drug reactions dur-
ing antidepressant drug treatment (e.g., [15–19]). How-
ever, even though genetic variation in CYP2D6 was 
one of the robust genetic variants associated with anti-
depressant drug response in the meta-analyses [11,12], 
studies conducted in both the STAR*D and GENDEP 
trials did not confirm these results [20,21], although 
GENDEP showed that genetic variation in CYP2D6 
was associated with serum  concentrations of both 
 escitalopram and nortriptyline [20].
In addition, also two independent genes that are 
related to antidepressant pharmaco dynamics have 
been identified in relation to antidepressant drug 
response, SLC6A4 and HTR2A [11,12,22]. Both genes 
encode for proteins that affect the synaptic cleft of 
serotonergic neurons, and SLC6A4 encodes the sero-
tonin reuptake transporter, the main pharmaco logical 
target of SSRIs [11,12,22]. Nevertheless, more genes 
have been identified in studies in relation to anti-
depressant drug response in depression, including for 
example FKBP5 and BDNF, but evidence is weaker 
(e.g., hetero geneity between studies is larger or studies 
were conducted with limited sample size) and requires 
additional studies to fully elucidate their role in anti-
depressant drug response in depression. Although a 
small number of genes have been repeatedly associated 
with anti depressant drug response in depression, the 
clinical benefit of knowing the status of these genes is 
considered to be limited at this time [12]. Furthermore, 
genome-wide association studies (GWAS), that aimed 
to identify genetic variants in relation to anti depressant 
drug response across the genome without having a pre-
defined hypothesis [23–27], have not detected genetic 
loci associated with antidepressant drug response that 
reached the level of statistical significance, not even 
the above-mentioned genes that have been previously 
reported in relation to antidepressant drug response in 
depression.
Within the present review, our main aim is to pro-
vide an overview of the methodological limitations 
and challenges associated with genetic studies of anti-
depressant response in depression. Next, we will dis-
cuss how specifically drug–gene interaction models 
in studies can contribute to identify genetic variants 
affecting antidepressant drug response in depression.
Challenges to identify genetic loci 
associated with antidepressant response in 
depression
One of the major challenges to the identification of 
genetic loci associated with antidepressant response is 
low statistical power, especially in the GWAS that have 
been published to date [23–27]. For example, a recently 
published meta-analysis had a discovery sample of 
865 MDD patients in which a GWAS was conducted, 
and the meta-analysis that also included the replica-
tion samples had a total sample size of 2394 MDD 
patients [27]. With such relatively small sample sizes, 
the identification of significant effects at the accepted 
GWAS significance threshold of p < 5 × 10-8 would 
require very large effect sizes on decrease in depressive 
symptoms over time. For this reason, larger collaborat-
ing efforts, as were also required to identify genetic loci 
in other phenotypes (e.g., [28,29]), are likely required to 
have well-powered studies to identify genetic loci with 
modest effects on the decrease in depressive symp-
toms [30]. Besides increasing the sample size, researchers 
have also applied other solutions to overcome the issues 
of the sample size, which includes studies of inter-
mediate phenotypes. However, also this strategy has 
some important limitations that need to be considered. 
For example, a GWAS on plasma drug concentrations 
of citalopram and escitalopram, which was performed 
in 435 MDD patients, identified two genome-wide sig-
nificant independent loci that included the CYP2C9 
and CYP2D6 genes [31]. These genes are encoding for 
proteins that affect drug metabolism. However, stud-
ies as these are not able to identify genes affecting 
antidepressant pharmaco dynamics [31]. Furthermore, 
although genetic variation in CYP2D6 is also associ-
ated with citalopram and nortriptyline in the GEN-
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DEP trial, no significant association was observed 
with drug response [20]. The clinical implication with 
respect to antidepressant drug response needs therefore 
to be elucidated.
An additional option for an intermediate phenotype 
could be, theoretically, the prescribed anti depressant 
dosage, as has also been done to identify loci involved 
in treatment resistance to coumarins [32–34]. How-
ever, coumarin treatment is precisely titrated by ref-
erence to the international normalized ratio (INR) 
while any antidepressant dose titration would rely on 
clinical response (unless blood levels are assessed on 
a regular basis). In the case of antidepressant drugs, 
participants at the upper end of the dosage phenotype 
distribution will include patients who were prescribed 
a higher prescribed antidepressant dosage because of a 
more severe type of depression as well as patients who 
were prescribed a higher antidepressant dosage because 
of nonresponse.
Of equal importance is the choice of the design 
to be able to identify genetic variants associated with 
antidepressant drug response. The study design most 
commonly used to date in genomic studies of anti-
depressant drug response is the ‘treated-only’ design, 
which is restricted to MDD patients who initiate 
antidepressant treatment and who are then followed 
over time to characterize treatment resistance. As was 
shown before in simulation models [35], genetic vari-
ants related with response in a treated-only design 
could theoretically reflect the main effect of the SNP 
on the indication of use. For example, it has been pre-
viously shown that antidepressant drugs have only a 
significant benefit over placebo treatment in patients 
with severe depressive symptoms [36]. When a study 
consists of a heterogeneous population of patients with 
mild and severe depressive symptoms, a larger drop 
in depressive symptoms during follow-up could theo-
retically be restricted to individuals with more severe 
depressive symptoms. In this scenario, genes associ-
ated with more severe depressive symptoms could thus 
be associated with heterogeneous antidepressant drug 
response. Although the effect of baseline severity of the 
depressive symptoms can be decreased by taking the 
percentage decrease in depressive symptoms, which is 
done in a limited number of the studies, this effect esti-
mate can still be in part dependent on the severity of 
the depressive symptoms at baseline. Genes that have 
been previously published in relation with depressive 
symptoms or MDD as well as with antidepressant drug 
response could be examples of genes that only show an 
association with antidepressant drug response because 
of their association with a subset of severe depres-
sive symptoms. Indeed, a systemic review and meta-
analysis reported that the S variant of the HTTLPR 
polymorphism in the SLC6A4 gene, a variant that has 
been repeatedly associated with antidepressant drug 
response [12], was associated with an 11% higher risk of 
MDD [37]. In theory, the observed association between 
SLC6A4 and antidepressant drug response also could 
be influenced by the association between SLC6A4 and 
the risk of MDD, and the true effect of SLC6A4 on 
the therapeutic response of antidepressants could be 
in theory be smaller. Yang et al. observed that genetic 
variation in the APC gene was associated with both 
MDD as well as with the therapeutic response to anti-
depressants [38]. In addition to these examples, more 
genes have been shown to associate both to MDD as 
well as to the decrease in depressive symptoms after 
initiation of treatment (e.g., [18]). As no reference group 
was taken into account in the pharmaco genetic analy-
sis, it is currently unknown whether or not these vari-
ants are truly associated with the therapeutic response 
of antidepressants in depression [38] or simply reflect 
genetic main effects.
An additional challenge to successfully identify 
genetic variants associated with antidepressant drug 
response is the reduction in depressive symptoms that 
is unrelated to the use of antidepressant drugs them-
selves [39], which is fairly common following anti-
depressant drug treatment in MDD patients. When 
people with MDD are enrolled at the height of their 
symptoms, subsequent improvement may be spontane-
ous, the response to the nonpharmaco logical part of 
treatment, or the result of ‘regression to the mean’ [40]. 
This issue is visualized in Figure 1, in which a hypo-
thetical placebo-controlled randomized trial on anti-
depressant response in depression is displayed. Here, 
both the group treated with antidepressants and the 
placebo-treated group showed significant reduction 
in depressive symptoms. However, one should take 
into account that only the area displayed in gray is 
attributable to the use of the antidepressant. When a 
treated-only design (with only depressive patients that 
are treated) is used to identify loci associated with anti-
depressant drug response in depression, the decrease 
in depressive symptoms will be in part be the result of 
the antidepressant drug treatment, but is also in part 
un related to the antidepressant drug treatment. In this 
case, both the depressive indication of anti depressants as 
well as the natural disease course of the depression can 
influence the results from a pharmaco genomic study 
on antidepressant drug response in depression. Again, 
taking into account an untreated reference population 
may be able to disentangle the reduction of depressive 
symptoms caused by the drug with the reduction of 
depressive symptoms caused by nonpharmaco logical 
reasons (e.g., if patients expect improvement because 
of receiving treatment) or by the natural disease course.
1032 Pharmaco genomics (2016) 17(9)
Figure 1. Hypothetical randomized clinical trial on antidepressant response. The dark gray area reflects the 
difference in response between depressive patients treated with antidepressant drugs depressive patients treated 
with placebo.
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Taken together, studies using a treated-only design 
to identify genetic variants associated with antidepres-
sant drug response in depression will not only identify 
loci that are associated with the therapeutic response 
of the antidepressant drug treatment, but also iden-
tify loci associated with the severity of the depressive 
indication and with the natural disease course of the 
depression. As we describe below, choosing a study 
design that includes a reference population with simi-
lar indication that is using placebo treatment will be 
able to disentangle the true antidepressant response 
related to the drug from the ‘response’ that is unrelated 
to the use of antidepressants.
Drug–gene interaction models in 
 pharmacogenetic studies
In epidemiology, interaction terms are used to demon-
strate whether the association between a determinant 
and outcome is modified by another factor. This way, 
patients at excessively high risk to develop a certain 
disease can be identified. For pharmaco genomics, this 
means that the association between the drug and out-
come is modified by certain genetic factors, and that 
patients with excessively high risk to develop adverse 
drug reactions or treatment resistance can be identified. 
However, these so-called ‘drug–gene interaction stud-
ies’ to identify pharmaco genetic loci that are associated 
with response or adverse drug reactions are not often 
performed. Using collaborative efforts, the ‘Cohorts 
for Heart and Aging Research in Genomic Epidemi-
ology’ consortium [41] aimed to identify genetic loci 
that interact with drug use on multiple outcomes of 
drug use. However, neither genome-wide drug–gene 
interaction studies of antihypertensive agents and car-
diovascular disease outcomes [42] nor of predefined 
drug classes and QT interval [43] identified genetic 
loci at genome-wide significant thresholds. Although 
these results could mean that there are no genetic loci 
that substantially modify the association between the 
drug and study outcome (and thus have no or limited 
clinical importance), the statistical power of these 
studies could also be too limited. Notably, the statis-
tical power of a genome-wide drug–gene interaction 
study is dependent on multiple factors [43]. First, the 
frequency of drug use in the study population should 
be sufficient, with less commonly used drugs neces-
sitating larger study populations. Second, the effect 
size should be substantial at least for the interaction, 
otherwise larger sample sizes are required. And third, 
the effect size of the drug on the outcome of interest. 
In case of a fairly low effect size of the drug on the 
outcome (e.g., a rare adverse drug event or a relatively 
small intended drug effect), a larger study population 
is required. Because of the issue of a limited sample 
size, new statistical programs have been developed 
to further increase the statistical power by leveraging 
longitudinal drug and phenotype assessments often 
available in prospective cohort studies [44], which can 
considerably increase statistical power [43].
Despite indications of a better performance of 
studies that use drug–gene interaction analyses, stud-
ies analyzing the effect of a SNP on the change of the 
study outcome after initiation of drug treatment can 
still provide valuable results. For example, several loci 
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were identified in a GWAS on cholesterol lowering 
in users of statin therapy [45]. Loci that were identi-
fied with the change in LDL cholesterol level after 
initiation of statin therapy include SORT1, SLCO1B1, 
APOE and LPA. Besides being related to change in 
LDL cholesterol level after initiation of statin therapy, 
three of these loci (notably SORT1, APOE and LPA) 
have also been identified in relation to LDL choles-
terol level in the most recent GWAS [46]. Based on the 
simulation studies described earlier, these loci could, 
besides being related to the LDL cholesterol lower-
ing response of statins, also be related to the main 
effect of the SNP on LDL cholesterol level [35], despite 
having adjusted for the baseline LDL cholesterol 
level [45]. Similar as discussed before, these genes do 
not necessarily reflect the biological mechanism how 
statins lower LDL cholesterol level despite showing an 
association with LDL cholesterol reduction in statin 
users. Different from antidepressant drug response 
in depression is that the response unrelated to the 
drug itself (e.g., placebo response or natural relief 
in depressive symptoms; Figure 1) is smaller in users 
of statins because LDL-cholesterol concentrations 
will not decrease spontaneously or as part of a dis-
ease course (e.g., [47]). This particular issue has been 
raised in a review by Hall et al. who showed that sev-
eral genetic variants are associated with the placebo 
response [48]. In case of the pharmaco genetics of anti-
depressant drug response, several genes of particular 
interest to the field (e.g., TPH2, SLC6A4, HTR2A) 
are highlighted in this paper to be genes involved 
in placebo response. As we highlighted above that a 
relatively large placebo effect is a likely cause of the 
difficulties with antidepressant pharmaco genomics, 
it is not surprising that all genetic loci for LDL 
 cholesterol  reduction in statin users were replicated in 
a drug–gene interaction analysis [45].
Together with the simulation analyses [35], it is likely 
that the chance of successfully identifying genetic loci 
with the therapeutic response is dependent on the 
choice of the design. For drugs such as antidepressants, 
that have a relatively small ‘true therapeutic effect’ 
(drug treatment effect – placebo treatment effect) [36], 
taking into account a reference group could therefore 
have important implications.
Application & considerations of drug–gene 
interaction models in pharmaco genetic 
randomized clinical trials on antidepressant 
response
To the best of our knowledge, no studies have yet stud-
ied the association between genetic variants and anti-
depressant drug response in depression using drug–gene 
interaction models in a population containing a group 
of MDD patients treated with an anti depressants as 
well as a reference group (e.g., MDD patients treated 
with placebo). Nevertheless, a limited number of stud-
ies compared their results with a placebo-treated popu-
lation [49], used a model-based approach to define the 
nonspecific response [50], or evaluated whether SNPs 
are specifically associated with response in nortriptyline 
or escitalopram [51]. In the case of a formal drug–gene 
interaction analysis, both the group of patients treated 
with an antidepressant drug and the group of patients 
treated with placebo would be followed over time and 
the depressive symptoms would be assessed at multiple 
time points. This procedure is exactly the same as what 
has been used to determine whether an antidepres-
sant drug is more effective than a placebo [36]. Within 
this setting a drug–gene interaction model will deter-
mine whether a genetic variant is associated with the 
decrease in depressive symptoms in the group treated 
with an antidepressant relative to the group treated 
with placebo. The regression formulas for the statisti-
cal analyses for the treated-only and place-controlled 
 pharmaco genomics study are as  follows:
Regression formula for treated-only designs
Change in depressive symptoms = α + β
1
 × SNP + βs 
for covariates 
Regression formula for drug–gene 
interaction models in randomized clinical 
trials
Change in depressive symptoms = α + β
1
 × 
SNP + β
2
 × (drug/placebo group) + β
3
 × SNP × (drug/
placebo group) + βs for covariates
In these formulas, α is the intercept of the regression 
line and the βs reflect the effect size of the independent 
variable on the change in depressive symptoms over 
time. In the treated-only design, β
1
 measures the effect 
size of the SNP on the drug effect (e.g., reduction in 
depressive symptoms) in users. For the regression for-
mula that is required in drug–gene interaction models 
in placebo-controlled studies, β
3
 reflects the effect size 
of the effect allele on the change in depressive symp-
toms over time in users of antidepressants relative to 
the placebo group. In case of the treated-only design 
β
1
 is the beta estimate of interest whereas in the pla-
cebo-controlled pharmaco genomic study β
3
 is the beta 
 estimate of interest.
Hypothetical examples of two situations of a drug–
gene interaction analysis in a placebo-controlled 
pharmaco genomic study are presented in Figure 2. 
According to the hypothetical situation depicted in 
the upper two graphs of the figure (Figure 2A), car-
riers of the variant allele (for simplicity reasons we 
combine heterozygous and homozygous variant allele 
1034 Pharmaco genomics (2016) 17(9)
Figure 2. Hypothetical drug–gene interaction situations in a randomized clinical trial on antidepressant drug 
response in depression. The trajectory of the depressive symptoms over time is depicted in antidepressant-
treated patients as a solid line, and in placebo-treated patients as a dashed line. (A) Carriers of the variant allele 
(heterozygous and homozygous carriers combined for simplicity reasons) are associated with, on average, a larger 
decrease in depressive symptoms than homozygous carriers of the major allele, but the effect size is similar for 
users of antidepressant treatment and users of placebo treatment. (B) Carriers of the variant allele that use also 
antidepressant treatment have a steeper decline in depressive symptoms within the time period than homozygous 
carriers of the major allele and users of placebo treatment. This hypothetical genetic variant is therefore a 
modifier of antidepressant drug response.
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carriers together in the examples) showed a larger 
reduction in the proportion of patients with clinical 
depressive symptoms over time than homozygous car-
riers of the major allele. However, the decrease in the 
proportion of patients with depressive symptoms over 
time is similar for users of antidepressant treatment 
(solid line) and for users of placebo treatment (dashed 
line). This indicates that, although associated with a 
faster relief in depressive symptoms, this allele is not 
modifying the antidepressant drug response. If we 
would have used a treated-only design, the conclu-
sion for this specific hypothetical allele would be that 
it is associated with antidepressant drug response in 
depression. However, as the association of this genetic 
variant is similar in the placebo-treated group, this 
hypothetical allele is more likely to reflect associa-
tions with depressive indicators or natural disease 
course. In contrast, true drug–gene interactions are 
shown in Figure 2B. In this example, the variant allele 
has no effect on reducing the severity of the depres-
www.futuremedicine.com 1035
Figure 3. Hypothetical drug–gene interaction situations in a (prospective) cohort study on antidepressant drug 
response in depression. (A) No interaction and no association with cross-sectional assessments of depressive 
symptoms. (B) No interaction but association with cross-sectional assessments of depressive symptoms. 
(C) Interaction present, only association with cross-sectional assessments of depressive symptoms in treated 
participants.
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sive symptoms in patients with depression treated 
with placebo, as the proportion of patients with 
clinical depressive symptoms at day 180 is similar to 
that observed among homozygous patients carrying 
the major allele. However, in patients treated with 
an antidepressant (solid line) who carry the variant 
allele, we observe a larger reduction in the proportion 
of patients with clinical depressive symptoms com-
pared with homozygous patients carrying the major 
allele or patients carrying the variant allele, but who 
treated with placebo (dashed line). Therefore, the 
variant allele in this hypothetical situation demon-
strates an allele that modifies therapeutic response to 
antidepressants in depression.
Based on these hypothetical examples that are likely 
also influencing already published findings, the use 
of a reference population in studies that aim to iden-
tify genetic variants in antidepressant response will be 
able to disentangle the loci that are associated with the 
natural disease course or depressive indicators from the 
loci that truly modify antidepressant drug response in 
depression.
Drug–gene interaction analyses in 
population-based cohort studies
In addition to randomized controlled clinical trials, 
population-based cohort studies also can have valu-
able data available to identify genetic loci associated 
with response to antidepressants. For contributing 
in such studies, cohorts should have data available 
on drug use and have cross-sectional assessments 
of depressive symptoms collected concurrently [52]. 
Importantly, data on depressive symptoms should 
be collected for the total (unselected) study popula-
tion. We defined genetic loci as being potential loci 
affecting antidepressant drug response in depres-
sion when genetic variants are associated with a 
different depressive symptoms score between users 
of antidepressants and nonusers of any antidepres-
sant drug. The rationale of this theory is visualized 
in Figure 3, where interaction between the SNP and 
drug is present only in Figure 3C (the association 
between the genetic variant and depressive symp-
toms score is different between users and nonusers 
of anti depressants). In Figure 3B, the SNP is associ-
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ated with depressive symptoms, but the association 
does not differ between treated and untreated indi-
viduals. Therefore, this locus is likely not associated 
with the therapeutic response, but instead with the 
depressive indication. In Figure 3A, there was interac-
tion nor an association between the genetic variant 
and depressive symptoms. Likely, this variant has no 
role in depression nor with the  therapeutic response 
to  antidepressants in depression.
To test the hypothesis that drug–gene interaction 
models can also be used to identify SNPs related to 
therapeutic response to antidepressants, we conducted 
a drug–gene interaction analysis in the prospective 
population-based Rotterdam Study cohort [53]. The 
Rotterdam Study, comparable to other population-
based cohort studies, was originally designed to study 
the incidence of, and risk factors for, age-related dis-
eases, and had no inclusion criteria other than being 
older than 55 years of age. During center visits, which 
took place every 4–5 years, data on depressive symp-
toms (center of epidemiological studies depression 
score or CES-D score) were collected, and data on 
use of drugs were continuously monitored [54]. Taking 
into account longitudinal data during which infor-
mation on depressive symptoms was collected [44], we 
identified two potential interesting loci on a genome-
wide level that interacted with the use of SSRIs on 
the depressive symptoms score (notably FSHR and 
HMGB4). Although a role in response to SSRIs has 
to be confirmed in future studies, mRNA expression 
levels were altered after stimulation with an SSRI in 
lower model organisms [55,56]. When we restricted our 
analysis to only genes that are involved in the sero-
tonin signaling pathway [57,58], we identified genetic 
variation in the PLCB1 gene, which encodes for a 
postsynaptic signal transduction protein, to sig-
nificantly interact with SSRI use on cross-sectional 
assessments of depressive symptoms. Although not 
earlier described in the literature in relation to antide-
pressant drug response in depression, common genetic 
variation in PLCB1 has been included in a patent of 
a pharmaco genetic testing kit for anti depressant drug 
response [59]. Further more, we observed that com-
mon genetic variation in the HTR2A gene interacted 
with use of SSRIs on depressive symptoms, which 
can be seen as additional confirmation of the role 
of HTR2A in the therapeutic response of SSRIs in 
depression [12,22].
However, although being a promising model for 
future studies on the genetic basis of antidepressant 
drug response in depression, there are some impor-
tant limitations that need to be taken into account. 
For example, it should be noted that antidepressants 
were prescribed for indication other than depression. 
In case of The Netherlands, SSRIs are most often pre-
scribed for depressive indications [6], but participants 
with an SSRI prescribed for another indication might 
negatively affect the study results. Furthermore, this 
approach does also not take into account factors asso-
ciated with a GP’s decision whether or not to initiate 
antidepressant drug treatment in case of a diagnosed 
MDD. As long as the genetic variant is unrelated to 
the indication ‘depression’ as well as with factors 
related to the choice of treatment, this will result in 
increased heterogeneity and variation in the outcome, 
meaning that the observed effect sizes are likely under-
estimated. In any case, larger sample sizes are required. 
Furthermore, as already highlighted earlier, it should 
be taken into account that for drug–gene interaction 
analyses in cohort studies using cross-sectional assess-
ments of depressive symptoms requires large sample 
sizes, especially to capture genetic variants with a rela-
tively low effect size and relatively low allele frequency. 
Nevertheless, future studies that are done with larger 
sample sizes will likely provide additional insights in 
the underlying biology of antidepressant treatment 
resistance in depression. However, significant inter-
actions from these type of studies should be replicated 
in placebo-controlled trials, as in theory the scenario 
depicted in Figure 3C can also be the other way around 
when the SNP is associated with depressive symptoms 
in untreated individuals, but not in treated  individuals. 
Visualization, as done in our study in case of the 
HTR2A findings [53], is one way to understand whether 
the observed interaction is driven by the treated or 
untreated individuals.
Conclusion & future perspective
With the increased possibilities to study genetic 
determinants in relation to certain study outcomes, 
researchers all over the world recognized the pos-
sibilities to increase the accuracy to predict disease 
outcomes and investigated the possibilities of preci-
sion medicine. Despite many initiatives, only a hand-
ful of genetic loci have been repeatedly associated 
with antidepressant drug response in depression [12]. 
These loci, however, could theoretically also be associ-
ated with aspects of decrease in depressive symptoms 
that are unrelated to the use of an antidepressant 
drug, including the depressive indication as well as 
the natural disease course of the depression. Further-
more, studies aiming to identify genetic loci associ-
ated with antidepressant drug response in depression 
are often performed with a small number of depres-
sive patients, including the GWAS which have been 
done to identify new genetic variants associated with 
antidepressant drug response. For example, the larg-
est GWAS to date on lipid lowering during statin 
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therapy required more than 18,000 users of statin 
therapy to identify four independent genetic vari-
ants associated with LDL cholesterol lowering after 
initiation of statin treatment [45]. Still, these identi-
fied loci explained only approximately 5% of the total 
variation in LDL cholesterol response in statin users. 
Although successful in identifying genetic markers 
in relation to cholesterol-lowering response in statin 
users, there is still a long way to accurately predict 
before initiation of statin treatment whether a patient 
will develop sufficient lowering in cholesterol level or 
not. A meta-analysis of the GENDEP, MARS and 
STAR*D trials on the association between genetic 
variants and antidepressant drug response in depres-
sion only comprised 2256 treated MDD patients, and 
no loci were identified that reached the level of sta-
tistical significance [26]. Therefore, also with respect 
to other pharmaco genomic studies on other pheno-
types, this indicates that the sample size is one major 
limitation [60]. Drug–gene interaction studies on anti-
depressant drug response in depression should also be 
aware of this, as such studies normally require larger 
sample sizes.
In summary, the search for genetic markers associ-
ated with antidepressant drug response in depression 
is difficult and only moderately successful to date. 
Although some genetic loci associated with antide-
pressant treatment have been replicated by others, 
generally the heterogeneity is large between studies, 
possible because of the lack of a reference popula-
tion in the design of the study. Drug–gene interac-
tion models, which additionally take into account 
the association between the genetic variant and the 
reduction in depression symptoms that is unrelated to 
the use of the antidepressant, will probably increase 
the ability to identify new loci and to confirm some 
of the already identified loci. This will also mean 
that loci previously associated with antidepressant 
drug response in depression in a treated-only design 
could be left unconfirmed in these newer drug–gene 
interaction studies. We expect that drug–gene inter-
action models will reduce the heterogeneity between 
studies and will increase the list of loci affecting 
the therapeutic response of antidepressants. When 
ethical issues prevent the use of a placebo-reference 
population especially in studies to be conducted in 
severe cases of MDD, studies can selected different 
reference population in their study design, including 
a reference population on psychotherapy or on dif-
ferent antidepressant drug treatment. Nevertheless, 
studies should be performed in larger (collaborative) 
settings to increase the statistical power whatever the 
composition of the reference population is. Likely, the 
use of drug–gene interaction models will increase our 
understanding of the genetic basis of  antidepressant 
response.
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Executive summary
•	 Although many studies have been conducted aiming to identify genetic variants in relation to antidepressant 
drug response in depression, only few genes have been repeatedly and robustly identified, notably CYP2D6, 
ABCB1, SLC6A4 and HTR2A.
•	 Important limitations of studies that have been conducted include the used sample size (and thus statistical 
power), but also the study design itself: the so-called ‘treated-only design’ in which only treated depressive 
patients are followed in time.
•	 The reduction in depressive symptoms that is observed in a study with a treated-only design can have 
different origins, including the indication of use, the natural disease course of the depressive indication 
(independent of drug use) and the true response of the antidepressant drug treatment.
•	 The inclusion of a reference group, such as a placebo-treated population, could disentangle the mix of origins 
why depressive patients show a decrease in depressive symptoms over time.
•	 The drug–gene interaction model in a placebo-controlled trial investigates what genetic variants associate 
with antidepressant drug response in antidepressant-treated depressive patients beyond the association that 
is observed in placebo-treated depressive patients.
•	 Genetic variants associated with ‘antidepressant response’ in both antidepressant-treated depressive patients 
and placebo-treated depressive patients are unlikely variants involved in antidepressant drug response in 
depression.
•	 Drug–gene interaction models in prospective cohort studies, in which genetic variants are differently 
associated with depressive symptoms in antidepressant-treated participants and untreated participants, 
might be an alternative strategy to identify genetic variants of interest for antidepressant drug response in 
depression.
•	 Future studies might benefit to investigate drug–gene interactions instead of main effects to identify genes 
for antidepressant drug response in depression.
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